Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases

A method of inhibiting or preventing cytokine production in a patient, the cytokine production caused by a food allergen, the method comprising:

• administering a therapeutically effective amount of two thiol isomerase inhibitors to a patient in need thereof;
• wherein the thiol isomerase inhibitor is a protein disulfide isomerase (PDI) inhibitor;
• and wherein the thiol isomerase inhibitor is a compound in the class of propynoic acid carbamoyl methyl amides (PACMAs) selected from the group consisting of PACMA 31 (N-(2,4-dimethoxypheny 1)-N-(1-oxo-2- propyn-1-yl)-2-(2-thienyl)glycylglycine ethyl ester);
• juniferdin;
• juniferdin epoxide;
• phenylarsine oxide;
• LOC 14 (2-[[4-(cyclopropylcarbonyl)-1-piperazinyllmethy 11-1,2-benzisothiazol-3(2H)-one);
• CCF 642 (3-(4-methoxypheny 1)-5-[(5-nitro-2- thienyl)methylene 1-2-thioxo-4-thiazolidinone);
• P1 (N-[(1,1-dimethylethoxy)carbonyll-L- phenylalanyl1-O-(ethenylsulfonyl1)-N-4-pentyn-1-yl-L -tyrosinamide);
• 1 6F1 6 (2-(2- chloroacety 1)-2,3 ,4,9-tetrahydro-1-methyl- 1H-pyrido[3,4-blindole-1-carboxylic acid methyl ester);
• ML359 (ethyl 1 -(3-chloro-4-hydroxybenzy 1)-4-(2-phenoxyethyl)piperidine-4- carboxylate);
• zafirlukast;
• CGP- 13501;
• CGP-7930;
• alosetron;
• balsalazide;
• benserazide;
• butaclamol;
• oxcarbazepine;
• or combination thereof, or a protein disulfide isomerase inhibitor targeting antibody, selected from the group consisting of protein disulfide isomerase inhibitor antibody RL90, or MA3-0 19, and wherein the therapeutically effective amount of the two thiol isomerase inhibitors is formulated as a pharmaceutical composition suitable for administration orally, parenterally, by inhalation or spray, transdermally, or rectally.